Cataract Devices Market Size, Share, Growth and Forecast (2026 - 2036)

Cataract Devices Market Forecast and Outlook By Fact.MR

• The cataract devices market was valued at USD 14.7 billion in 2025.
• According to Fact.MR, demand is projected to reach USD 15.3 billion in 2026 and expand to USD 23.8 billion by 2036, reflecting a CAGR of 4.5% during the forecast period.

Summary of Cataract Devices Market

• Market Definition
  • The market includes cataract surgery devices used for lens removal, anterior chamber protection, surgical visualization, and intraocular lens implantation.
• Demand Drivers
  • Ophthalmic surgeons are using advanced phaco systems and IOLs where cataract surgery demand is rising among ageing populations.
  • Hospitals need efficient cataract platforms because procedure backlogs and outpatient care models require faster surgical throughput.
  • Ambulatory surgical centers are adopting compact cataract systems where day-case surgery and faster recovery support patient turnover.
• Key Segments Analyzed
  • By Product Type: Intraocular lenses are expected to hold approximately 42.0% share in 2026, supported by their essential role after cataract removal.
  • By Application: Nuclear sclerotic cataracts lead in 2026 with about 28.0% share, due to broad age-related occurrence.
  • By End User: Hospitals account for around 50.0% share in 2026, supported by access to surgical infrastructure and specialist staff.
  • By Sales Channel: Direct institutional sales are projected to hold 45.0% share in 2026, as hospitals and surgery centers prefer qualified supply.
  • By Technology: Phacoemulsification is expected to account for nearly 46.0% share in 2026, supported by its role in routine lens removal.
  • By Geography: China leads growth through 2036 at 6.1% CAGR, supported by wider cataract surgery access and ophthalmic capacity expansion.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Senior Analyst at Fact.MR, states, “Cataract device demand is no longer tied only to procedure count. The stronger shift is toward surgical efficiency, premium lens selection, patient recovery expectations, and outpatient cataract workflows. Suppliers that can support lens customization, reliable phaco performance, and surgeon training will hold stronger positions than companies competing only on device availability.”
• Strategic Implications
  • Manufacturers should strengthen premium IOL portfolios because patients increasingly expect better post-surgery visual outcomes.
  • Hospitals need reliable phaco and visualization platforms to improve surgical throughput and reduce procedural delays.
  • Distributors should support surgeon training and timely device supply because cataract surgery schedules depend on product availability.
• Methodology
  • Market sizing uses cataract procedure demand, IOL utilization, phaco system adoption, product pricing, and care-site distribution.
  • Analysis includes FDA device references, WHO eye care resources, NICE cataract guidance, ophthalmology society resources, and company product data.
  • Forecasts account for ageing populations, outpatient surgery expansion, premium IOL adoption, cataract backlog reduction, and regional surgical capacity.

The market is projected to generate USD 8.5 billion in absolute opportunity between 2026 and 2036. Growth is supported by cataract surgery volumes, wider use of intraocular lenses, and greater adoption of phacoemulsification systems. WHO states that cataract surgery is among the most cost-effective health-care interventions, while access gaps remain across several countries. [1]

China leads with a projected CAGR of 6.1% through 2036, supported by ophthalmic infrastructure expansion and cataract surgery access. South Korea follows at 5.8%, helped by advanced eye care adoption and premium lens demand. Germany grows at 5.7%, backed by surgical precision systems and strong clinic networks. The USA records 5.6%, with demand anchored in outpatient surgery and IOL adoption. Japan posts 5.6%, supported by ageing demographics and advanced ophthalmic care. France grows at 5.5%, helped by ambulatory cataract surgery and public reimbursement systems.

Segmental Analysis

Cataract Devices Market Analysis by Product Type

Intraocular lenses are expected to hold 42.0% share in 2026 as every cataract surgery requires lens replacement after removal of the clouded natural lens. Standard monofocal IOLs remain important in public and routine surgery settings. Premium IOLs gain use where patients seek better post-surgery visual function. Phacoemulsification equipment remains central because most cataract procedures rely on controlled lens fragmentation and removal. Femtosecond lasers and visualization systems support premium surgical workflows, but higher capital investment slows wider use. FDA describes the IC-8 Apthera IOL as an artificial lens implanted after cataract removal, reinforcing the central role of IOLs in cataract procedures. [2]

• Lens Replacement: IOLs remain essential because the clouded natural lens must be replaced after cataract removal.
• Phaco Dependence: Phacoemulsification systems support controlled lens removal across routine and complex cases.
• Premium Upgrade: Multifocal and toric IOLs gain demand where patients seek better near or astigmatism correction.

Cataract Devices Market Analysis by Application

Nuclear sclerotic cataracts lead because this cataract type is strongly linked with ageing and lens hardening. These cases often require phaco systems, IOL implantation, and surgical visualization suited to age-related lens changes. The segment is expected to account for 28.0% share in 2026. Posterior sub-capsular cataracts create demand where glare and reading vision are affected earlier. Cortical cataracts add demand through lens opacity patterns that affect visual quality. Congenital and traumatic cataracts remain smaller but clinically important categories. Poor screening can delay surgery and increase avoidable visual impairment.

• Age-Linked Burden: Nuclear sclerotic cataracts remain common because lens opacity rises with ageing.
• Precision Need: Posterior sub-capsular cases need accurate diagnosis and suitable surgical planning.
• Complex Cases: Congenital and traumatic cataracts require specialized devices and experienced surgical care.

Cataract Devices Market Analysis by End User

Hospitals lead demand because cataract surgery often requires operating rooms, skilled ophthalmic surgeons, sterilization systems, imaging support, and postoperative care pathways. Advanced hospitals handle high-volume cataract surgery and complex cases requiring specialized equipment. Hospitals are estimated to hold 50.0% share in 2026. Ophthalmic clinics are gaining demand through outpatient cataract procedures and specialized eye care workflows. Ambulatory surgical centers support faster turnover where day-case procedures are clinically suitable. Academic and training institutes contribute demand through surgeon education and technology evaluation. Weak infrastructure can reduce throughput and affect patient access.

• Surgical Infrastructure: Hospitals provide operating rooms and specialist support for routine and complex cataract surgery.
• Clinic Efficiency: Ophthalmic clinics support outpatient procedures where workflow speed matters.
• Training Demand: Academic institutes help surgeons adopt newer IOLs, phaco systems, and visualization platforms.

Cataract Devices Market Analysis by Sales Channel

Hospitals and surgery centers prefer supplier relationships that can support IOL supply, phaco system servicing, and product upgrades. Distributor sales remain important in emerging markets and smaller clinics where local access matters. Group contract sales support large hospital networks that standardize device sourcing. Direct institutional sales are expected to account for 45.0% share in 2026 because cataract devices require clinical documentation, surgeon training, service support, and equipment maintenance. Online medical supply plays a limited role because cataract devices need stronger qualification and technical service. Low-support channels can struggle when surgeons need rapid replacement supply.

• Contract Reliability: Direct sales help hospitals maintain IOL and device availability across surgical schedules.
• Service Support: Phaco systems and laser platforms need maintenance and clinical support.
• Distributor Access: Regional distributors help smaller clinics manage device availability and replenishment.

Cataract Devices Market Analysis by Technology

Phacoemulsification remains the core technology because it supports small-incision cataract surgery and established surgeon workflows. Femtosecond laser-assisted systems gain use where precision, capsulotomy consistency, and premium procedure positioning matter. Image-guided visualization platforms are gaining relevance in high-volume eye centers that seek workflow control. The technology base is estimated to hold 46.0% share in 2026. Optical biometry and planning systems support IOL selection and refractive outcomes. AAO patient education describes IOLs as artificial lenses replacing the natural lens removed during cataract surgery, which links device demand directly with surgical workflow. Poor equipment uptime can disrupt procedure scheduling and reduce operating room efficiency. [3]

• Phaco Workflow: Phacoemulsification remains central because surgeons rely on it for routine lens removal.
• Laser Precision: Femtosecond systems gain use where premium cataract workflows justify higher capital cost.
• Planning Support: Biometry and visualization systems help surgeons improve lens selection and procedural control.

Drivers, Restraints, and Opportunities

Rising cataract burden and ageing demographics are increasing demand for devices that support safe and efficient cataract surgery. WHO states that eyeglasses for refractive error and cataract surgery are among the most cost-effective health-care interventions, but access gaps remain significant. Hospitals and eye centers are placing more value on phaco systems, IOL platforms, and surgical planning tools that support consistent outcomes. Premium IOL adoption is improving where patients are willing to pay for better post-surgery visual function.

High equipment cost and uneven surgical access restrain faster growth. Femtosecond lasers, advanced visualization platforms, and premium IOL systems require capital budgets, surgeon training, and service support. Public healthcare systems may prioritize standard IOLs and routine phaco procedures over premium technologies. Cataract surgery backlogs can increase demand, but workforce shortages and uneven regional access can slow procedure expansion. Device suppliers must prove clinical value, service reliability, and affordability before wider adoption.

• Premium IOL Adoption: Toric and multifocal lenses create opportunity where patients seek lower dependence on glasses after surgery.
• Outpatient Cataract Surgery: Ambulatory surgery centers create demand for compact systems and efficient procedure-ready device supply.
• High-Volume Programs: Emerging markets need durable cataract devices that balance affordability, reliability, and surgical throughput.

Regional Analysis

The cataract devices market is assessed across North America, Europe, Asia Pacific, Latin America, and Middle East and Africa, covering 30+ countries with demand profiles shaped by cataract prevalence, surgical infrastructure, outpatient procedure access, reimbursement, device regulation, and ophthalmologist availability.

Source: Fact.MR analysis, based on proprietary forecasting model and primary research.

Asia Pacific Cataract Devices Market Analysis

Asia Pacific records the strongest growth because cataract surgery access, ophthalmic infrastructure, and patient awareness are expanding together. China and South Korea are adding demand through urban hospital modernization and wider adoption of premium cataract technologies. Japan supports steady demand through ageing demographics and advanced ophthalmic care. The region contains both high-end surgical centers and price-sensitive public systems. Suppliers need portfolios that balance phaco reliability, IOL affordability, and premium lens availability. Growth depends on procedure capacity, surgeon training, and product access across urban and semi-urban care settings.

• China: China is predicted to reach 6.1% CAGR from 2026 to 2036 as ophthalmic infrastructure expansion supports higher cataract procedure access. Public and private eye care programs are improving patient reach in major cities and secondary centers. Premium IOLs are gaining acceptance in advanced urban hospitals, where patients are more willing to consider visual outcome upgrades. Suppliers with training support, localized distribution, and dependable IOL availability can capture stronger institutional demand.
• South Korea: Advanced surgical care and premium vision expectations are strengthening cataract device use in South Korea. Ophthalmic clinics and hospitals use phaco systems, premium IOLs, and visualization platforms to support outpatient cataract procedures. Demand is forecast to advance at 5.8% CAGR by 2036 as patients seek sharper post-surgery outcomes and lower dependence on corrective lenses. Suppliers with refractive cataract portfolios and strong clinic relationships are better placed in this market.
• Japan: Ageing demographics and advanced ophthalmic care keep Japan’s cataract procedure base stable. Hospitals and eye clinics use phaco systems, IOLs, and biometry platforms to support predictable surgical outcomes. Japan is anticipated to reach 5.6% CAGR over the assessment period. Service reliability, high-quality lenses, and products suited to careful clinical workflows remain important for supplier selection.

North America Cataract Devices Market Analysis

North America remains a high-value region because cataract surgery volumes, outpatient care models, and premium IOL adoption support device demand. The United States anchors regional revenue through hospitals, ambulatory surgical centers, and ophthalmic clinics. FDA device approvals and patient safety review shape access to new IOL designs and surgical technologies. Buyers evaluate cataract devices through clinical evidence, surgeon preference, equipment uptime, and reimbursement fit. Demand remains stable, but capital cost and reimbursement limits affect faster adoption of premium systems. [4]

• USA: A large cataract surgery base and established outpatient infrastructure support device demand in the United States. The USA is expected to expand at 5.6% CAGR by 2036 as ambulatory surgery centers and ophthalmic clinics continue to manage high procedure volume. Medicare-linked access keeps routine cataract surgery stable, while premium IOL adoption adds value in selected patient groups. Purchasers examine product performance, service support, and reimbursement compatibility before expanding technology adoption.

Europe Cataract Devices Market Analysis

Europe shows steady demand because cataract surgery pathways, medical device regulation, and hospital purchasing systems are structured. Germany and France represent strong demand patterns across specialist clinics, public reimbursement, and advanced ophthalmology services. NICE guidance on cataracts in adults emphasizes referral, surgical management, and complication reduction, supporting structured care pathways. Hospitals and clinics emphasize documentation, device reliability, and surgical workflow integration. Growth remains moderate because many European systems already have established cataract surgery programs. [5]

• Germany: Dense ophthalmic clinic networks and strong surgical technology adoption support Germany’s cataract devices market. Demand is linked to phaco systems, IOL delivery platforms, and surgical visualization tools. Germany is anticipated to account for 5.7% over the study period, remains one of Europe’s stronger cataract device growth markets. Suppliers with advanced service support, surgeon education, and clinical documentation can protect institutional demand across public and private care settings.
• France: Public reimbursement and ambulatory cataract surgery support procedure access in France. Ophthalmology centers use IOLs, phaco systems, and diagnostic planning tools to improve patient outcomes. France is likely to post 5.5% CAGR through 2036 as day-case surgical pathways and structured eye care access support consistent device consumption. Suppliers with strong product availability and evidence-backed lens portfolios can improve hospital and clinic adoption.

Fact.MR analysis of regional demand covers North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The study assesses cataract procedure capacity, IOL demand, phaco system adoption, outpatient care growth, reimbursement, device regulation, and supplier support across major markets.

Competitive Aligners for Market Players

The cataract devices market is moderately concentrated in premium IOLs, phaco platforms, and femtosecond laser systems, but more fragmented across regional device supply and lower-cost product categories. Large global suppliers hold advantages because surgeon training, clinical evidence, service infrastructure, and hospital contracts create switching barriers. Smaller suppliers often compete through affordability, regional distribution, and product availability for high-volume programs.

Competitive advantage depends on IOL portfolio depth, phaco system reliability, surgical visualization quality, service uptime, and surgeon education. Johnson & Johnson, Carl Zeiss Meditec, Bausch + Lomb, Hoya Corporation, Staar Surgical, NIDEK, Aurolabs, Biotech Healthcare Group, Ophtec, VSY Biotechnology, and Ziemer Ophthalmic Systems represent supplier groups where clinical credibility and distribution reach matter. Hospitals and clinics are less likely to switch platforms when surgeons are trained on specific equipment and lens systems.

The market is divided between premium cataract technologies used in advanced centers and cost-efficient devices used in high-volume surgery programs. Suppliers that combine reliable product performance with training, documentation, and service support can protect institutional demand. Regional companies can gain ground where affordability and local supply matter more than global brand positioning.

Key Players

• Johnson & Johnson
• Carl Zeiss Meditec AG
• Bausch & Lomb
• Hoya Corporation
• Staar Surgical
• NIDEK CO., LTD
• Aurolabs
• Biotech Healthcare Group
• Ophtec BV
• VSY Biotechnology BV
• Ziemer Ophthalmic Systems AG
• Alcon Inc.

Bibliography

• [1] World Health Organization. (2026). Blindness and vision impairment. WHO.
• [2] United States Food and Drug Administration. (2022). IC-8 Apthera intraocular lens (IOL): P210005. FDA.
• [3] American Academy of Ophthalmology. (2024). IOL implants: Lens replacement after cataracts. AAO.
• [4] United States Food and Drug Administration. (2021). TECNIS Synergy intraocular lens approval. FDA.
• [5] National Institute for Health and Care Excellence. (2017). Cataracts in adults: Management. NICE.

This Report Addresses

• Strategic intelligence on cataract device demand across phacoemulsification systems, intraocular lenses, femtosecond lasers, ophthalmic viscoelastic devices, and surgical visualization platforms globally.
• Market forecast from USD 15.3 billion in 2026 to USD 23.8 billion by 2036 at a CAGR of 4.5%.
• Growth opportunity mapping across China cataract surgery access, South Korea premium lens adoption, Germany surgical technology use, U.S. outpatient cataract procedures, Japan ageing-linked procedure demand, and France ambulatory care expansion.
• Segment analysis by product type, application, end user, sales channel, technology, and region.
• Regional outlook covering Asia Pacific surgical access growth, North America outpatient cataract surgery demand, and Europe structured surgical pathway adoption.
• Competitive analysis of Johnson & Johnson, Carl Zeiss Meditec, Bausch & Lomb, Hoya Corporation, NIDEK, Aurolabs, Biotech Healthcare Group, and Alcon.
• Product adoption analysis covering phaco reliability, IOL customization, femtosecond laser precision, visualization quality, surgeon training, service support, and reimbursement fit.
• Report delivered with market sizing, segment outlook, regional analysis, company profiling, and forecast assumptions.

Cataract Devices Market Definition

The market covers cataract devices used before, during, and after cataract surgery to diagnose lens opacity, remove the clouded lens, and restore vision through intraocular lens implantation. It includes phacoemulsification equipment, ophthalmic viscoelastic devices, femtosecond lasers, intraocular lenses, and surgical visualization systems used by hospitals, ophthalmic clinics, and ambulatory surgical centers.

Cataract Devices Market Inclusions

Covers global and regional forecasts from 2026 to 2036. Includes phacoemulsification equipment, OVDs, femtosecond lasers, monofocal IOLs, toric IOLs, multifocal IOLs, accommodative IOLs, and cataract surgery visualization systems. Includes devices used in nuclear sclerotic, cortical, posterior sub-capsular, congenital, and traumatic cataract procedures.

Cataract Devices Market Exclusions

Excludes general eye drops, spectacles, contact lenses, refractive surgery platforms not used for cataract treatment, glaucoma devices, retinal surgery systems, and standalone ophthalmic diagnostics not tied to cataract care. Focus remains on devices used directly in cataract surgery planning, lens removal, chamber protection, and post-removal vision restoration.

Cataract Devices Market Research Methodology

• Primary Research
  • Interviews with ophthalmic surgeons, cataract surgery center directors, hospital purchasing heads, ambulatory surgery center managers, IOL distributors, and ophthalmic device suppliers across major consuming regions.
• Desk Research
  • Uses FDA device approval references, WHO vision impairment resources, NICE cataract management guidance, ophthalmology society resources, company product catalogues, hospital purchasing references, and peer-reviewed clinical literature.
• Market-Sizing and Forecasting
  • Hybrid model using cataract procedure volumes, device utilization rates, IOL mix, phaco system adoption, outpatient surgery share, and average selling prices by product category.
• Data Validation and Update Cycle
  • Validated using supplier channel checks, hospital purchasing patterns, regulatory references, surgeon preference inputs, and product availability reviews. Updated annually.